NASDAQ:ANIP • US00182C1036
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ANI PHARMACEUTICALS INC (ANIP).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-16 | Guggenheim | Maintains | Buy -> Buy |
| 2025-12-09 | Barclays | Initiate | Overweight |
| 2025-11-10 | Guggenheim | Maintains | Buy -> Buy |
| 2025-10-09 | Truist Securities | Maintains | Hold -> Hold |
| 2025-09-24 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-09-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-08 | Guggenheim | Maintains | Buy -> Buy |
| 2025-08-11 | Truist Securities | Maintains | Hold -> Hold |
| 2025-08-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-07-10 | HC Wainwright & Co. | Initiate | Buy |
| 2025-05-12 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-04-21 | Truist Securities | Maintains | Hold -> Hold |
| 2025-04-11 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-03-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-14 | Jefferies | Initiate | Buy |
| 2025-03-12 | JP Morgan | Initiate | Overweight |
| 2025-03-05 | Guggenheim | Maintains | Buy -> Buy |
| 2025-03-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-11 | Leerink Partners | Initiate | Outperform |
| 2024-11-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-22 | Truist Securities | Maintains | Hold -> Hold |
| 2024-10-11 | Piper Sandler | Initiate | Overweight |
| 2024-09-18 | Raymond James | Maintains | Outperform -> Outperform |
| 2024-09-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-11 | Truist Securities | Downgrade | Buy -> Hold |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 316.4M 46.41% | 486.816M 53.86% | 614.376M 26.20% | 885.29M 44.10% | 1.059B 19.62% | 1.226B 15.77% | 1.296B 5.71% | 1.402B 8.18% | 1.525B 8.77% | 1.508B -1.11% | 1.547B 2.59% | 1.586B 2.52% | |
| EBITDA YoY % growth | 30.15M 55.81% | 107.894M 257.86% | 70.568M -34.60% | 229.2M 224.79% | 272.58M 18.93% | 332.47M 21.97% | 360.19M 8.34% | 417.95M 16.04% | 502.86M 20.32% | N/A | N/A | N/A | |
| EBIT YoY % growth | -29.5M -5.73% | 48.103M 263.06% | 2.837M -94.10% | 229.84M 8,001.52% | 280.94M 22.23% | 341.87M 21.69% | 144.74M -57.66% | 177.07M 22.34% | 214M 20.86% | N/A | N/A | N/A | |
| Operating Margin | -9.32% | 9.88% | 0.46% | 25.96% | 26.53% | 27.88% | 11.17% | 12.63% | 14.03% | N/A | N/A | N/A | |
| EPS YoY % growth | 1.41 -56.75% | 4.72 234.75% | 5.20 10.17% | 7.69 51.35% | 9.09 15.55% | 10.82 19.00% | 11.78 8.81% | 12.94 9.90% | 13.72 5.98% | 14.05 2.40% | 14.24 1.38% | 14.40 1.15% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 1.60 -6.00% | 2.21 22.94% | 2.36 15.50% | 2.59 11.25% |
| Revenue Q2Q % growth | 219.26M 11.23% | 251.35M 18.91% | 247.49M 8.64% | 268.95M 8.86% |
| EBITDA Q2Q % growth | 51.093M 4.09% | 63.072M 4.66% | 64.312M -39.39% | 78.009M 24.00% |
| EBIT Q2Q % growth | 43.627M 66.55% | 68.389M 385.30% | 80.297M 115.26% | 33.66M -45.95% |
All data in USD
14 analysts have analysed ANIP and the average price target is 111.91 USD. This implies a price increase of 58.76% is expected in the next year compared to the current price of 70.49.
ANI PHARMACEUTICALS INC (ANIP) will report earnings on 2026-05-07.
The consensus EPS estimate for the next earnings of ANI PHARMACEUTICALS INC (ANIP) is 1.6 USD and the consensus revenue estimate is 219.26M USD.
The consensus rating for ANI PHARMACEUTICALS INC (ANIP) is 84.2857 / 100 . This indicates that analysts generally have a positive outlook on the stock.